IGF 2 (Instant Growth Formula)

[Seattle Junk]

http://www.enhancement-watch.info/google/igf.php

Hahaha....sorry guys...had to do it....Somebody must know me cuz I get flooded with these emails in my hotmail junk folder.

[JohnnyB]

IGF-2 will cause gut growth too

JohnnyB

[Seattle Junk]

IGF-2 will cause gut growth too

JohnnyB

That GH gut looks terrible...When people say roid gut don't they mean GH gut? Prolonged use and high amounts of GH (& IGF1?) makes your internal organs grow as well. Enlarged heart is the most dangerous.

[dwaynewade]

That GH gut looks terrible...When people say roid gut don't they mean GH gut? Prolonged use and high amounts of GH (& IGF1?) makes your internal organs grow as well. Enlarged heart is the most dangerous.

igf-1??? internal organs... bump!

[JohnnyB]

That GH gut looks terrible...When people say roid gut don't they mean GH gut? Prolonged use and high amounts of GH (& IGF1?) makes your internal organs grow as well. Enlarged heart is the most dangerous.

LR3 IGF-1 doesn't cause gut growth, unless it used with an anti-inflammatory

JohnnyB

[JohnnyB]

The role of insulin-like growth factors in small intestinal cell growth and development.

MacDonald RS.

Nutritional Sciences Program, University of Missouri, Columbia, USA. [email protected]

IGF-I and IGF-II receptors are expressed in the small intestine of mammalian species, as are the genes to synthesize both peptides. IGF binding proteins are also expressed in the intestine. IGF-I and IGF-II mRNA are highest in fetal and newborn tissues and decrease with age. IGF-I mRNA is present in the adult small intestine, and is associated with the submucosal regions and crypt cells. IGF-I and IGF-II receptor binding to the small intestine is higher in newborn animals and decreases with age. Both receptors are more concentrated in the crypt than villus regions, but IGF-II binding is higher than IGF-I in all regions. IGF-I receptors are associated with the submucosal region of the small intestine, whereas IGF-II receptors are more abundant in the mucosal cells. Administration of IGF-I either orally or by osmotic pump generally has no affect on small intestinal weight or length, but does increase mucosal cellularity. LR3-IGF-I administration by osmotic pump affects the small intestine similarly to IGF-I, although with a higher potency. In the few studies in which IGF-II was administered, increased gut mass was observed in adult rats, but not newborn rats or pigs. Significant effects on mucosal expression of disaccharidases was achieved with either oral or subcutaneous IGF-I or oral IGF-II. Administration of IGF in models of intestinal hypertrophy and atrophy are also reviewed.

JohnnyB

[JohnnyB]

Dexamethasone is an anti-inflamitory

Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.

Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ.

CSIRO Division of Human Nutrition, Adelaide, South Australia.

The administration of insulin -like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats. Marked dose-dependent effects on body weight and nitrogen retention were produced, with the highest IGF-I dose, 695 micrograms/day, giving a 6 g increase in body weight over 7 days, compared with a 19 g loss in the dexamethasone-only group and an 18 g gain in pair-fed controls. Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I. The response with LR3IGF-I was particularly striking because this peptide binds 3-fold less well than IGF-I to the type 1 IGF receptor. The increased potencies of the IGF-I variants may relate to the substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3, produced by the combined treatment of dexamethasone with IGF-I or the variants. These binding proteins would be expected to decrease the transfer of IGF-I, but not that of the variants, from blood to tissue sites of action. Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes. Thus 3MH excretion was decreased at the highest IGF-I dose from 83.5 +/- 4.2 (S.E.M.) mumol/kg per 7 days to 65.1 +/- 2.2, compared with 54.9 +/- 1.2 in the pair-fed controls. Part of this response in 3MH excretion may have reflected a decrease in gut protein breakdown, because IGF-I and especially the IGF analogues increased the gut weight by up to 45%. Notwithstanding the effects on protein synthesis and breakdown, the fractional carcass weights remained low in the IGF-treated groups, although the increase in total carcass weight reflected nitrogen rather than fat gain. The dexamethasone-induced changes in liver, spleen and heart weight were restored towards normal by the IGF treatment. The experiment demonstrates the potential of IGF-I treatment of catabolic states and especially the value of modified forms of growth factors that bind weakly to IGF-binding proteins.

JohnnyB

[Sprinter1]

I sometimes take voltaren (anti-inflammatory) to help with groin pain when im doing speed work. I take about 75mgs, 2-3 times per week (225mg's) per week.

Would IGF1 LR3 use and the above dosage lead to gut growth?

Please advise, im anxious to know.